Lancet Regional Health-Americas最新文献

{"title":"Methodological considerations in the assessment of mortality risk among law enforcement officers","authors":"Atif Kamal","doi":"10.1016/j.lana.2025.101319","DOIUrl":"10.1016/j.lana.2025.101319","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101319"},"PeriodicalIF":7.0,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay between biological & social vulnerability and poor tuberculosis treatment outcome in Brazil: a nationwide study using multivariate modelling with excess risk","authors":"Beatriz Barreto-Duarte ,&nbsp;Klauss Villalva-Serra ,&nbsp;João P. Miguez-Pinto ,&nbsp;Mariana Araújo-Pereira ,&nbsp;Vanessa M.S. Campos ,&nbsp;Isabella B.B. Ferreira ,&nbsp;Betânia M.F. Nogueira ,&nbsp;Artur T.L. Queiroz ,&nbsp;Valeria C. Rolla ,&nbsp;Marcelo Cordeiro-Santos ,&nbsp;Afrânio L. Kritski ,&nbsp;Leonardo Martinez ,&nbsp;Peter F. Rebeiro ,&nbsp;Timothy R. Sterling ,&nbsp;Moreno M. Rodrigues ,&nbsp;Bruno B. Andrade","doi":"10.1016/j.lana.2025.101305","DOIUrl":"10.1016/j.lana.2025.101305","url":null,"abstract":"<div><h3>Background</h3><div>Focusing on socially vulnerable sub-populations at increased risk of tuberculosis is warranted to decrease the disease burden. In this study, we evaluated whether homelessness, living with HIV, incarceration, pregnancy, immigration, drug use, and healthcare work are inter-related risk factors for unfavorable anti-tuberculosis treatment (ATT) outcomes in Brazil through analysis of national disease registry database (SINAN).</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of tuberculosis cases ≥18 years-old reported to SINAN between 2015 and 2023. Clinical and epidemiologic variables were compared between groups (non-vulnerability, homeless, people deprived of their liberty, pregnant women, people with HIV, people who use drugs, immigrants and healthcare worker). Bivariate comparisons identified characteristics associated with a composite unfavorable ATT outcome, or specifically death or LTFU versus cure. Multivariate modelling with relative excess risk due to interactions (RERI) were calculated to estimate how co-occurring vulnerabilities further increase the risk of unfavorable outcomes.</div></div><div><h3>Findings</h3><div>Among 679,572 cases analysed, most were males aged 18−35 years-old, with non-white ethnicity. 16% of individuals without vulnerabilities experienced unfavourable outcomes, compared to 33% among those with at least one vulnerability. Overlapping vulnerabilities further amplified risk: for instance, unfavourable outcomes occurred in more than 67% of individuals who reported both homelessness and drug use. Interaction analyses revealed both synergistic and antagonistic effects, with the strongest additive synergy observed between HIV infection and drug use, with a RERI of 225% [174–304%].</div></div><div><h3>Interpretation</h3><div>The superposition of interlacing social and biological vulnerabilities significantly worsened the risk of both death and LTFU in our population. Our study demonstrates that the joint effect of vulnerabilities on TB outcomes is not merely additive, but often synergistic, highlighting the importance of integrated and multisectoral interventions. These findings hallmark the need for policies that simultaneously address social and biological vulnerabilities to improve ATT success.</div></div><div><h3>Funding</h3><div><span>Intramural Research Program-Oswaldo Cruz Foundation</span>.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101305"},"PeriodicalIF":7.0,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimorbidity profile among cancer-related hospitalization events in younger and older patients: a large-scale nationwide cross-sectional study","authors":"Yanara A. Bernal ,&nbsp;Carla Campaña ,&nbsp;Cristobal Sanhueza ,&nbsp;Mauricio Apablaza ,&nbsp;Ricardo Armisén ,&nbsp;Iris Delgado","doi":"10.1016/j.lana.2025.101308","DOIUrl":"10.1016/j.lana.2025.101308","url":null,"abstract":"<div><h3>Background</h3><div>Multimorbidity, the coexistence of two or more chronic diseases, among cancer patients offers critical insights into shared risk factors, while posing increasing challenges for healthcare systems due to the complexity of care required. Despite its relevance, research in multimorbidity across different age groups is limited in middle income countries.</div></div><div><h3>Methods</h3><div>We analyzed cancer-related hospitalizations between 2019 and 2023, using a nationwide Diagnosis-Related Groups database covering 68 Chilean health institutions. We examined the distribution of 40 chronic conditions, multimorbidity prevalence, comorbidity profile, and their distribution across age group, sex, and cancer diagnosis.</div></div><div><h3>Findings</h3><div>We identified 4,722,723 hospitalization events, including 149,270 unique adult patients hospitalized with cancer (mean of 63 ± 15.17 years old). Multimorbidity was present in 47.9% of all cancer-related hospitalizations, increasing steeply with age: 14% in patients aged 18–35, 24.9% in those 36–50, and 55.5% in patients &gt;50 years. Obesity and diabetes were among the most common comorbid conditions across age groups, with significant variations by sex. Notably, obesity was more prevalent in younger patients, particularly those aged 18–35, whereas hypertension showed an inverse profile, increasing markedly with age.</div></div><div><h3>Interpretation</h3><div>Multimorbidity profile reflect both the clinical complexity of cancer care and potential shared biological and environmental pathways in carcinogenesis. These findings highlight the need to transition from disease-centered to person-centered care models. In Chile, understanding multimorbidity in younger and middle-aged adults may inform precision prevention, integrated service delivery, and equitable planning for both oncologic and non-oncologic care.</div></div><div><h3>Funding</h3><div>This study was conducted without external funding.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101308"},"PeriodicalIF":7.0,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145623697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epistemic humility for physicians and scientists","authors":"Leo Anthony Celi ,&nbsp;Matilda Dorotic ,&nbsp;Joseph Dubin ,&nbsp;Noushin Nazarian ,&nbsp;Reza Salarikia","doi":"10.1016/j.lana.2025.101315","DOIUrl":"10.1016/j.lana.2025.101315","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101315"},"PeriodicalIF":7.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between optimized bismuth quadruple therapy and standard clarithromycin-based triple therapy for first-line Helicobacter pylori eradication: a double-blind randomized controlled trial","authors":"Patricio Andrés Medel-Jara ,&nbsp;Gonzalo Latorre ,&nbsp;Eduardo Fuentes-Lopez ,&nbsp;Margarita Pizarro ,&nbsp;Paola Viviani ,&nbsp;Javier Chahuán ,&nbsp;Sara Maquilón ,&nbsp;Oscar Corsi ,&nbsp;Diego Reyes ,&nbsp;Alberto Espino ,&nbsp;Jose Ignacio Vargas ,&nbsp;Ignacio A. Wichmann ,&nbsp;Paul Harris ,&nbsp;Carolina Serrano ,&nbsp;Isabella Buruato ,&nbsp;Christopher Sandoval ,&nbsp;Nelson M. Varela ,&nbsp;Leslie Cerpa ,&nbsp;Luis Quiñones ,&nbsp;Francis Megraud ,&nbsp;Arnoldo Riquelme Perez","doi":"10.1016/j.lana.2025.101312","DOIUrl":"10.1016/j.lana.2025.101312","url":null,"abstract":"<div><h3>Background</h3><div><em>Helicobacter pylori</em> eradication reduces the risk of peptic ulcer disease and gastric cancer. In Chile, the effectiveness of standard triple therapy has dropped below 80%. We compared <em>optimized bismuth quadruple therapy</em>: esomeprazole 40 mg three times a day, amoxicillin 1 gr three times a day, metronidazole 500 mg three times a day, and bismuth subsalicylate 369 mg three times a day for 14 days, and standard triple therapy omeprazole 20 mg twice a day, amoxicillin 1 gr twice a day, and clarithromycin 500 mg twice a day for 14 days in a Chilean population.</div></div><div><h3>Methods</h3><div>Randomized double-blind clinical trial. 127 treatment-naïve individuals with confirmed active <em>H. pylori</em> were recruited. The primary outcome was successful <em>H. pylori</em> eradication, at least 4 weeks post-treatment. We assessed <em>H. pylori</em> resistance to clarithromycin and participants’ <em>CYP2C19</em> genotype/phenotype. We compared eradication success between the groups using intention-to-treat and per-protocol analyses. The trial adhered to CONSORT guidelines. NTC-Number: <span><span>NCT05664685</span><svg><path></path></svg></span> (trial completed).</div></div><div><h3>Findings</h3><div>127 participants were recruited and randomized (64 standard triple therapy, 63 optimized bismuth quadruple therapy). Men were 44% (56/127), and the mean age was 48 (standard deviation: 14.2) in the sample. Baseline characteristics between the two groups were similar. In intention-to-treat analysis, optimized bismuth quadruple therapy had a significantly higher eradication rate versus standard triple therapy: 95% (60/63) [95% CI 86%–99%] vs. 81% (52/64) [70%–89%], p = 0.033. Adverse events were comparable: optimized bismuth quadruple therapy 67% (42/63) [54%–77%] vs. standard triple therapy 66% (42/64) [53%–76%], p = 1.00. There was no difference in baseline clarithromycin resistance or <em>CYP2C19</em> polymorphisms.</div></div><div><h3>Interpretation</h3><div>Optimized bismuth quadruple therapy eradication is higher than standard triple therapy in treatment-naïve individuals with active <em>H. pylori</em>, without difference in adverse events or adherence. Optimized bismuth quadruple therapy is a reliable and safe empiric eradication therapy, especially in areas with high clarithromycin resistance.</div></div><div><h3>Funding</h3><div><span>FONDECYT</span> (1230504 AR); <span>ANID-FONDAP</span> (152220002 AR); <span>Horizon 2020 program of European Union</span> (825832 AR); <span>ANID-FONDAP</span> (15130011).</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101312"},"PeriodicalIF":7.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 5 diabetes: a 70-year perspective and its implications for the Americas","authors":"Pradnyashree Wadivkar ,&nbsp;Debbie S. Thompson ,&nbsp;Meredith Shamamian ,&nbsp;Meredith Hawkins ,&nbsp;Michael S. Boyne","doi":"10.1016/j.lana.2025.101313","DOIUrl":"10.1016/j.lana.2025.101313","url":null,"abstract":"<div><div>Type 5 Diabetes (T5DM) was first identified by Hugh-Jones in Jamaica in 1955 as J-type diabetes. Since then, multiple reports from various countries have supported the idea that T5DM differs from other known forms of diabetes. Common features that distinguish T5DM include a body mass index of &lt;18.5 kg/m², low hepatic fat mass, low C-peptide concentrations, normal insulin sensitivity, and absence of ketoacidosis. Despite this unique phenotype, T5DM is often missed or misdiagnosed, potentially resulting in underreporting, though the magnitude is unknown. While the majority of Latin America and the Caribbean are experiencing a nutritional transition, chronic undernutrition still exists in some regions facing food insecurity and geopolitical conflicts, thus raising the risk for incident T5DM. This paper aims to highlight the 70-year history of T5DM, which began in the Americas, and proposes refocusing our attention on this underexplored but critical condition, which will probably continue to affect many individuals in the Americas.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"52 ","pages":"Article 101313"},"PeriodicalIF":7.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact and effectiveness of RSV maternal immunization on infant hospitalizations in Buenos Aires: a hospital-based, multicentre, retrospective surveillance cohort study","authors":"Josefina L. Razzini ,&nbsp;Daniela Parada ,&nbsp;Guillermo Solovey ,&nbsp;Gonzalo Guiñazú ,&nbsp;Emiliano M. Sosa ,&nbsp;Sabrina R. Orta ,&nbsp;Sofía Esposto ,&nbsp;Gabriela Sanluis Fenelli ,&nbsp;Anastasia E. Regalado ,&nbsp;Valeria Torre ,&nbsp;Micaela Pichinenda ,&nbsp;María Fabiana Ossorio ,&nbsp;Stella Maris Souto ,&nbsp;María Nieves Ojeda ,&nbsp;Silvana Lugo ,&nbsp;Fernando Ferrero ,&nbsp;Fernando P. Polack ,&nbsp;Julia Dvorkin ,&nbsp;Mauricio T. Caballero ,&nbsp;Florencia Cohen","doi":"10.1016/j.lana.2025.101296","DOIUrl":"10.1016/j.lana.2025.101296","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) is a major cause of hospitalizations and mortality in young infants worldwide. The RSVpreF maternal immunization (MI) was recently introduced in Argentina.</div></div><div><h3>Methods</h3><div>This study assessed the impact of RSVpreF MI on RSV-related acute lower respiratory tract infections (ALRTI) hospitalizations through a hospital-based, multicentre, retrospective surveillance cohort study, and measured vaccine effectiveness (VE) using a nested test-negative case–control study. Data of hospitalized infants under 18 months of age was collected and analysed within seven years from three Argentine tertiary hospitals. VE analysis included ALRTI-hospitalized infants who were born between March 1 and November 9, 2024, were under 6 months of age when tested for RSV, and whose mothers were eligible for prenatal RSV immunization. Expected RSV-ALRTI hospitalizations were compared with observed cases using a Poisson model. We estimated the VE of RSVpreF MI against RSV-ALRTI hospitalizations, paediatric intensive care unit (PICU) admissions, and extended hospital stays by comparing these rates in vaccinated and unvaccinated under 3 and 6 months.</div></div><div><h3>Findings</h3><div>A total of 3373 participants were included in the impact analysis, fromof whom 323 were born during the vaccination period and were eligible for the VE analysis. The VE of RSVpreF MI was 80·8% (95% CI: 62·8–90·5%), and 66·1% (95% CI 30·1–83·8) for infants under 3 and 6 months, respectively, adjusted for age, sex, comorbidities, and epidemiological weeks. VE for PICU admission was 87·2% (95% CI 52·6–97·0) and 88·6% (95% CI 62·3–97·1) for extended hospital stays in infants under 6 months. The vaccine reduced RSV-ALRTI hospitalizations in infants under 6 months by 33·6% (95% CI 29·5–37·2) in 2024 compared to expected cases from previous years. The number needed to immunize to prevent one RSV-related hospitalization was 83·9 (95% CI 65·9–185·4).</div></div><div><h3>Interpretation</h3><div>RSVpreF MI significantly reduced RSV-ALRTI hospitalizations, averting one-third of such hospitalizations in infants under 6 months. These findings provide valuable evidence for policymakers and health authorities.</div></div><div><h3>Funding</h3><div>Gates Foundation and Thrasher Research Fund.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"52 ","pages":"Article 101296"},"PeriodicalIF":7.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145568649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-disparate experiences and incidence of gender-based violence victimization of transgender women: findings from a cohort study in eastern and southern United States","authors":"Andrea L. Wirtz ,&nbsp;Elizabeth Humes ,&nbsp;Tonia C. Poteat ,&nbsp;Keri N. Althoff ,&nbsp;Kenneth H. Mayer ,&nbsp;Erin E. Cooney ,&nbsp;Meg Stevenson ,&nbsp;Ceza Pontes ,&nbsp;Asa E. Radix ,&nbsp;Andrew J. Wawrzyniak ,&nbsp;Sari L. Reisner","doi":"10.1016/j.lana.2025.101298","DOIUrl":"10.1016/j.lana.2025.101298","url":null,"abstract":"<div><h3>Background</h3><div>Gender-based violence (GBV) is a threat to health and human rights and experiences may vary with age. We estimated the incidence and correlates of GBV in transgender women in the United States.</div></div><div><h3>Methods</h3><div>From March 2018–August 2020, we enrolled a cohort (N = 1312) of transgender women without HIV in eastern and southern US. Participants were followed for 24–48 months via site-based and digital modes. We measured lifetime and recent (past 3 or 6 months) psychological, physical, and sexual GBV over follow-up. We calculated frequencies and incidence rates (IR) of each form of violence, stratified by age at enrollment (18–24 vs. ≥ 25 years). We used modified Poisson regression models to identify predictors of incident GBV and calculate adjusted relative risk (aRR) and 95% confidence intervals.</div></div><div><h3>Findings</h3><div>Participants were a mean age of 31years (standard deviation: 11) and 60% identified as White race (793/1312), 15% as Black (196/1312), and 19% as Hispanic/Latine (242/1312). At baseline, 88% (1140/1312) reported any lifetime GBV and 42% (546/1312) recent GBV. Psychological violence was most common (39% [507/1312] recent, 85% [1101/1312] lifetime), followed by physical (12% [151/1312] recent, 65% [843/1312] lifetime) and sexual (7% [94/1312] recent, 43% [557/1312] lifetime). Perpetrators were most frequently family members, partners, and strangers. Incidence of GBV was higher among young adults (IR = 119·4/100 person-years, 95% CI = 107·0–132·9) compared to adults (IR = 88·5/100 person-years, 95% CI = 81·7–95·6). Among young adults, online versus site-based participants had elevated GBV risk (aRR = 1·14, 95% CI = 1·03–1·26). Among adults, food insecurity (aRR:1·13, 95% CI:1·04–1·23), higher discrimination scores (aRR:1·01, 95% CI: 1·01–1·02), psychological distress (aRR:1·08, 95% CI:1·00–1·17), and drug use disorder symptoms (aRR:1·09, 95 CI:1·01–1·18) were associated with increased GBV risk. Other predictors were observed in age-specific models for incident psychological, physical, and sexual violence.</div></div><div><h3>Interpretation</h3><div>GBV is exceptionally high among US transgender women. Survivor services, protective policies, and interventions must explicitly address transgender women's needs, including age-specific GBV contexts.</div></div><div><h3>Funding</h3><div>NIH.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101298"},"PeriodicalIF":7.0,"publicationDate":"2025-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional cash transfer interventions to support syphilis treatment in vulnerable populations: a quasi-experimental study among displaced and host communities in a border city of Colombia","authors":"Merike Blofield ,&nbsp;Andrea L. Wirtz ,&nbsp;Magaly Pedraza ,&nbsp;Rafael Olarte ,&nbsp;Doris Parada","doi":"10.1016/j.lana.2025.101301","DOIUrl":"10.1016/j.lana.2025.101301","url":null,"abstract":"<div><h3>Background</h3><div>Syphilis incidence is increasing globally; however, cost and time are significant barriers to treatment completion rates among vulnerable populations, including displaced populations and host communities. To inform public health strategies, we aimed to test whether conditional cash transfers (CCT) increased completion of syphilis treatment among a community sample in a border city of Colombia.</div></div><div><h3>Methods</h3><div>We embedded a quasi-experimental trial of a CCT intervention in a community sexual health program serving participants aged 14 years and older in low-income settlements around Cúcuta, Colombia in 2023. The program included workshops and syphilis screening. Individuals with laboratory-confirmed syphilis were eligible for inclusion in the trial. Both control and CCT arms provided syphilis diagnostics, counseling and free treatment. CCT consisted of cash payments of USD$12.69 for completion of each of two follow-up treatments. We used generalized linear models to estimate the effect of CCT on treatment completion, defined as three doses of penicillin.</div></div><div><h3>Findings</h3><div>Of 1751 workshop participants, 114 had laboratory-confirmed syphilis and were enrolled in the trial. Participants were 56% female (64/114) and 44% male (50/114), with 6 participants (5.3%) identifying as transgender, regardless of sex at birth. Participants included 47% Venezuelan migrants staying in Cúcuta (53/114), 26% Colombian returnees (30/114), and 19% Colombians from the host community (22/114). Data on ethnicity was not collected. Median age was 34.5 years (IQR: 25.0–46.0). More than three-quarters (78%, 39/50) of CCT participants completed the three-dose treatment regimen compared to 45% (29/64) of control participants, a risk difference of 33% (p &lt; 0.001). In adjusted models, CCT-assigned participants had a 36% higher treatment completion rate compared to control-assigned participants (adjusted risk difference: aRD: 0.36, 95% CI: 0.19–0.53).</div></div><div><h3>Interpretation</h3><div>Conditional cash transfers might enhance syphilis treatment adherence among populations facing socioeconomic challenges.</div></div><div><h3>Funding</h3><div><span>German Development Cooperation Agency</span>, <span>Deutsche Gesellschaft für Internationale Zusammenarbeit</span>.</div></div>","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"53 ","pages":"Article 101301"},"PeriodicalIF":7.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145526894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study”- the Lancet Regional Health—Americas 2025; Volume 49: 101172; DOI: 10.1016/j.lana.2025.101172","authors":"Andrés F. Cardona ,&nbsp;Natalia Sánchez ,&nbsp;Liliana Gutiérrez-Babativ ,&nbsp;Leonardo Rojas ,&nbsp;Jairo Zuluaga ,&nbsp;Stella Martínez ,&nbsp;Lucia Viola ,&nbsp;Carlos Carvajal ,&nbsp;Juliana Bogoya ,&nbsp;Laura Prieto-Pinto ,&nbsp;Daniel Samacá-Samacá ,&nbsp;Antonio Robles ,&nbsp;Joshua Kock ,&nbsp;Claudio Martín ,&nbsp;Luis Corrales ,&nbsp;Luis E. Raez ,&nbsp;Vladmir Cordeiro de Lima ,&nbsp;Suraj Samtani ,&nbsp;Oscar Arrieta","doi":"10.1016/j.lana.2025.101300","DOIUrl":"10.1016/j.lana.2025.101300","url":null,"abstract":"","PeriodicalId":29783,"journal":{"name":"Lancet Regional Health-Americas","volume":"52 ","pages":"Article 101300"},"PeriodicalIF":7.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}